Inositol-isomer supplement combination · Fact sheet
Myo-inositol + D-chiro-inositol
Also known as MI/DCI blend · 40:1 inositol blend
Myo-inositol plus D-chiro-inositol is a combination studied in PCOS. Small trials explore ratios and metabolic or ovulation outcomes, but they do not establish a universally optimal ratio, fertility treatment or live-birth benefit.
What is Myo-inositol + D-chiro-inositol?
The two ingredients are different inositol stereoisomers. Their relative proportions can change the intervention.
A 40:1 ratio describes composition, not a complete dose or guarantee of clinical efficacy.
Benefits & claims
Interest in Myo-inositol + D-chiro-inositol spans hormone and reproductive health, metabolism. Study findings apply to the named formulation and population.
What the evidence supports
- The ratio study reported better ovulation-related findings in its 40:1 arm.
- Very small groups and multiple tested ratios limit the strength of an optimal-ratio claim.
- Ovulation and hormone measures do not by themselves establish improved live birth or long-term metabolic disease prevention.
Research areas
- Formulation-specific human outcomes
- Mechanistic research
Dosage & frequency
Human study contextThis is an exposure from a named human study, not a generally established treatment or enhancement regimen.
Seven-ratio PCOS study
56 people with PCOS; eight per ratio group
- Amount
- 2 g total inositols per administration; seven separately assigned ratios, including 40:1 MI/DCI
- Frequency
- Twice daily for three months
- Route studied or labeled
- Oral
The amount is the combined inositols, not 2 g of each. Small groups do not establish a universally best ratio or live-birth benefit; this is distinct from other trials with added ingredients.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- The two ingredients are different inositol stereoisomers. Their relative proportions can change the intervention.The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Formulation differences
- A 40:1 ratio describes composition, not a complete dose or guarantee of clinical efficacy.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Side effects & risks
- Reproductive, pregnancy and long-term safety require evidence beyond small short studies.
- Results cannot be generalized across ratios, ingredient identities and products that add folate or other compounds.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceA 56-person ratio study had only eight participants per group. A separate 50-person comparison found early metabolic differences but no significant between-group differences at six months.
Studies
56 PCOS participants across seven ratio groups.
50 overweight women with PCOS; combination versus myo-inositol alone.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
No FDA-approved Myo-inositol + D-chiro-inositol drug indication is established for the supplement uses discussed here. Supplement availability is not FDA approval of efficacy or safety.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
- The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
- FDA: what approval means for supplements
Open questions
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Summary
Ovulation and hormone measures do not by themselves establish improved live birth or long-term metabolic disease prevention.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedThe 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
56 PCOS participants across seven ratio groups.
- pubmedThe combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
50 overweight women with PCOS; combination versus myo-inositol alone.
- fdaFDA: what approval means for supplements
Dietary supplements are not approved by FDA for safety and effectiveness before marketing.